Obsidian Therapeutics: Below, Which Were Not Previously Filed With The Original Filing, And Which Are Permitted To Be Filed By Amendment No Later Than 71 Calendar Days After The Date The Original Filing Was Required To Be Filed With The Sec. No Other Changes Have Been Made To The Original Filing. This Amendment No. 1 Should Be Read In Conjunction With The Original Filing. Capitalized Terms Used Herein That Are Not Otherwise Defined Shall Have The Meanings Set Forth In The Original Filing

Item 9.01 below, which were not previously filed with the Original Filing, and which are permitted to be filed by amendment no later than 71 calendar days after the date the Original Filing was required to be filed with the SEC. No other changes have been made to the Original Filing. This Amendment No. 1 should be read in conjunction with the Original Filing. Capitalized terms used herein that are not otherwise defined shall have the meanings set forth in the Original Filing. The pro forma financial information included as Exhibit 99.3 to this Amendment No. 1 has been presented for illustrative purposes only, as required by Form 8-K, and is not intended to, and does not purport to, represent what the combined company’s actual results or financial condition would have been if the Mergers had occurred on the relevant date, and is not intended to project the future results or financial condition that the combined company may achieve following the Mergers. Item 9.01. Financial Statements and Exhibits.(a) Financial Statements of Businesses or Funds Acquired.The audited financial statements of Obsidian Therapeutics Sub, Inc. for the years ended December 31, 2025 and 2024 and the related notes thereto are included in the information statement/prospectus which formed a part of the Registration Statement, and are incorporated herein by reference.The unaudited condensed consolidated financial statements of Obsidian Therapeutics Sub, Inc., as of June 30, 2026, and for the six months ended June 30, 2026 and 2025 are filed as Exhibit 99.1 hereto and are incorporated herein by reference.The unaudited management's discussion and analysis of financial condition and results of operations of Obsidian Therapeutics Sub, Inc., as of June 30, 2026 is filed as Exhibit 99.2 hereto and are incorporated herein by reference.(b) Pro Forma Financial Information.The unaudited pro forma condensed combined financial statements of Obsidian Therapeutics, Inc., as of and for the six months ended June 30, 2026, are filed as Exhibit 99.3 hereto and are incorporated herein by reference.(c) Shell Company Transactions.None.(d) Exhibits. ExhibitNo. Description 99.1 Unaudited condensed consolidated financial statements of Obsidian Therapeutics Sub, Inc., as of June 30, 2026 and for the six months ended June 30, 2026 and 2025. 99.2 Unaudited Management's Discussion and Analysis of financial condition and results of operations of Obsidian Therapeutics Sub, Inc., as of June 30, 2026. 99.3 Unaudited pro forma condensed combined financial statements of Obsidian Therapeutics, Inc., as of and for the six months ended June 30, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OBSIDIAN THERAPEUTICS, INC. Date: August 14, 2026 By: /s/ Madan Jagasia Name: Madan Jagasia Title: Chief Executive Officer, Director

Autres actualités de l'entreprise